The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs
Open accessAbstract
Most of the cytotoxic chemotherapeutic agents have poor aqueous solubility. These molecules are associated with poor physicochemical and biopharmaceutical properties, which makes the formulation difficult. An important approach in this regard is the use of combination of cyclodextrin and nanotechnology in delivery system. This paper provides an overview of limitations associated with anticancer drugs, their complexation with cyclodextrins, loading/encapsulating the complexed drugs into carriers, and various approaches used for the delivery. The present review article aims to assess the utility of cyclodextrin-based carriers like liposomes, niosomes, nanoparticles, micelles, millirods, and siRNA for delivery of antineoplastic agents. These systems based on cyclodextrin complexation and nanotechnology will camouflage the undesirable properties of drug and lead to synergistic or additive effect. Cyclodextrin-based nanotechnology seems to provide better therapeutic effect and sustain long life of healthy and recovered cells. Still, considerable study on delivery system and administration routes of cyclodextrin-based carriers is necessary with respect to their pharmacokinetics and toxicology to substantiate their safety and efficiency. In future, it would be possible to resolve the conventional and current issues associated with the development and commercialization of antineoplastic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“In passive targeting, liposomes, macromolecular carriers, and nanoparticles exploit the EPR effect, which is a consequence of the increased vasculature permeability and decreased lymphatic function of tumors, to target the drug to the tumor [74].”
BackgroundAmidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Introduction and General Overview of Cyclodextrin Chemistry
Szejtli, J. (1998) · Chemical Reviews · doi:10.1021/cr970022c · Cited by 5,016
Cyclodextrins and their uses: a review
Del Valle, E. M. M. (2004) · Process Biochemistry · doi:10.1016/s0032-9592(03)00258-9 · Cited by 3,375
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Improving drug solubility for oral delivery using solid dispersions
Leuner, C. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00076-x · Cited by 2,574
Cyclodextrins and their inclusion complexes
Szejtli, J. (1982) · REAL-EOD (Library of the Hungarian Academy of Sciences and the Information Center Oriental Collection) · Cited by 1,680
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Serajuddin, A. T. M. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js980403l · Cited by 1,648
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,415
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Nanosizing: a formulation approach for poorly-water-soluble compounds
Merisko-Liversidge, E., Liversidge, G. G., & Cooper, E. R. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00251-8 · Cited by 1,263
Drug Development and Industrial Pharmacy
Rhodes, C. T. (1995) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049509070870 · Cited by 1,263
Cyclodextrins in drug delivery: An updated review
Challa, R., Ahuja, A., Ali, J., & Khar, R. K. (2005) · AAPS PharmSciTech · doi:10.1208/pt060243 · Cited by 1,215
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
Aakeroy, C. B. (1997) · Journal of Chemical Crystallography · doi:10.1007/bf03543092 · Cited by 1,137
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Cyclodextrin-based supramolecular polymers
Harada, A., Takashima, Y., & Yamaguchi, H. (2009) · Chemical Society Reviews · doi:10.1039/b705458k · Cited by 861
Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery
Rajewski, R. A., & Stella, V. J. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js960075u · Cited by 824
Melt extrusion: from process to drug delivery technology
Breitenbach, J. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00061-9 · Cited by 742
Stella, V. J., & He, Q. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310945 · Cited by 700
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development
Szente, L. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00092-1 · Cited by 540
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502
Cyclodextrin based novel drug delivery systems
Vyas, A., Saraf, S., & Saraf, S. (2008) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-008-9456-y · Cited by 412
Self-citationEnhancement of transdermal drug delivery via synergistic action of chemicals
Karande, P., & Mitragotri, S. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.08.015 · Cited by 399
Swaminathan, S., Pastero, L., Serpe, L., Trotta, F., Vavia, P., Aquilano, D., Trotta, M., Zara, G., & Cavalli, R. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.11.003 · Cited by 358
Cellular mechanisms of multidrug resistance of tumor cells.
Stavrovskaya, A. A. (2000) · PubMed · Cited by 344
Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma
Dhule, S. S., Penfornis, P., Frazier, T., Walker, R., Feldman, J., Tan, G., He, J., Alb, A., John, V., & Pochampally, R. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.07.011 · Cited by 299
Cyclodextrin-based Nanosponges for Drug Delivery
Cavalli, R., Trotta, F., & Tumiatti, W. (2006) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-006-9085-2 · Cited by 292
Role of Cyclodextrins in Improving Oral Drug Delivery
Loftsson, T., Brewster, M. E., & M??sson, M. (2004) · American Journal of Drug Delivery · doi:10.2165/00137696-200402040-00006 · Cited by 287
Cancer Stem Cells: A Step Toward the Cure
Boman, B. M., & Wicha, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7436 · Cited by 278
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Synthesis, characterization and application of Epichlorohydrin-β-cyclodextrin polymer
Gidwani, B., & Vyas, A. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.09.035 · Cited by 206
Self-citationCyclodextrins: application in different routes of drug administration.
Shimpi, S., Chauhan, B., & Shimpi, P. C. (2005) · PubMed · Cited by 173
Liu, T., Li, X., Qian, Y., Hu, X., & Liu, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.013 · Cited by 170
Walter, R. B., Raden, B. W., Kamikura, D. M., Cooper, J. A., & Bernstein, I. D. (2004) · Blood · doi:10.1182/blood-2004-07-2784 · Cited by 155
Cancer-Targeted Polymeric Drugs
Luo, Y., & Prestwich, G. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023333836 · Cited by 147
Li, J. (2010) · NPG Asia Materials · doi:10.1038/asiamat.2010.84 · Cited by 146
Agüeros, M., Ruiz-Gatón, L., Vauthier, C., Bouchemal, K., Espuelas, S., Ponchel, G., & Irache, J. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.09.010 · Cited by 139
Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin
Eid, E. E. M., Abdul, A. B., Suliman, F. E. O., Sukari, M. A., Rasedee, A., & Fatah, S. S. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.10.033 · Cited by 133
Çırpanlı, Y., Bilensoy, E., Doğan, A. L., & Çalış, S. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.04.013 · Cited by 127
Spontaneous Opalescence of Aqueous γ-Cyclodextrin Solutions: Complex Formation or Self-Aggregation?
Szente, L., Szejtli, J., & Kis, G. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9704341 · Cited by 126
Cyclodextrins in drug delivery systems
Otero-Espinar, F. J., Torres-Labandeira, J. J., Alvarez‐Lorenzo, C., & Blanco-Méndez, J. (2010) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(10)50046-7 · Cited by 123
Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review
Chaturvedi, K., Ganguly, K., Kulkarni, A. R., Kulkarni, V. H., Nadagouda, M. N., Rudzinski, W. E., & Aminabhavi, T. M. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.610790 · Cited by 114
Voriconazole—a new therapeutic agent with an extended spectrum of antifungal activity
Donnelly, J. P., & Pauw, B. E. D. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00838.x · Cited by 112
Johns, T. G., Luwor, R. B., Murone, C., Walker, F., Weinstock, J., Vitali, A. A., Perera, R. M., Jungbluth, A. A., Stockert, E., Old, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036503100 · Cited by 107
Recent Trends in Niosome as Vesicular Drug Delivery System
Sankhyan, A., & Pawar, P. K. (2012) · Cited by 94
Badruddoza, A. Z. M., Rahman, M. T., Ghosh, S., Hossain, M. Z., Shi, J., Hidajat, K., & Uddin, M. S. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2013.02.046 · Cited by 91
Approved monoclonal antibodies for cancer therapy
Boyiadzis, M. M., & Foon, K. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1151 · Cited by 87
Kim, C., Shah, B. P., Subramaniam, P., & Lee, K. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100460h · Cited by 86
Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether
Kim, Y., Oksanen, D. A., Massefski, W. W., Blake, J. F., Duffy, E. M., & Chrunyk, B. A. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980109t · Cited by 80
Cortés, M. E., Sinisterra, R. D., Ávila-Campos, M. J., Tortamano, N., & Rocha, R. G. (2001) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1023/a:1012788432106 · Cited by 79
Bilensoy, E., Çırpanlı, Y., Şen, M., et al. (2007) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-006-9259-y · Cited by 77
Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities
Béni, S., Szakács, Z., Csernák, O., Barcza, L., & Noszál, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.10.008 · Cited by 72
Inhaled corticosteroids for asthma: are they all the same?
Baptist, A. P., & Reddy, R. C. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00970.x · Cited by 71
Design of Nanoparticles as Drug Carriers for Cancer Therapy.
Zhang, J., Lan, C. Q., Post, M. L., Simard, B., Deslandes, Y., & Hsieh, T. H. (2006) · PubMed · Cited by 71
McCormack, B., & Gregoriadis, G. (1996) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00096-7 · Cited by 66
Alternative oral exemestane formulation: Improved dissolution and permeation
Yavuz, B., Bilensoy, E., Vural, İ., & Şumnu, M. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.046 · Cited by 66
Elgindy, N. A., Elkhodairy, K. A., Molokhia, A., et al. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.11.011 · Cited by 66
Clinical pharmacology of anticancer agents in relation to formulations and administration routes
Terwogt, J. M. M., Schellens, J. H. M., Huinink, W. W. T. B., & Beijnen, J. H. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1998.0107 · Cited by 64
Deng, J., Li, N., Mai, K., Yang, C. H., Yan, L., & Zhang, L. (2011) · Journal of Materials Chemistry · doi:10.1039/c0jm03030a · Cited by 53
Monnaert, V., Betbeder, D., Fénart, L., Bricout, H., Lenfant, A., Landry, C., Cecchelli, R., Monflier, É., & Tilloy, S. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071845 · Cited by 53
Wang, F., Saidel, G. M., & Gao, J. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.01.019 · Cited by 49
Paolino, D., Licciardi, M., Celia, C., Giammona, G., Fresta, M., & Cavallaro, G. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.06.001 · Cited by 46
Modulating β‐lapachone release from polymer millirods through cyclodextrin complexation
Wang, F., Blanco, E., Ai, H., Boothman, D. A., & Gao, J. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20721 · Cited by 42
Interaction of Modified Cyclodextrins with Cytochrome P-450
Ishikawa, M., Yoshii, H., & Furuta, T. (2005) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.69.246 · Cited by 39
Layre, A., Gosselet, M., Renard, E., Sébille, B., & Amiel, C. (2002) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1023/a:1021287920274 · Cited by 38
García‐Rodríguez, J. J., Torrado, J. J., & Bolás-Fernández, F. (2001) · Parasite · doi:10.1051/parasite/200108s2188 · Cited by 38
ORIGINAL ARTICLE: Solubilization of vorinostat by cyclodextrins
Cai, Y., Yap, C. W., Wang, Z., Ho, P. C., Chan, S. Y., Ng, K. Y., Ge, Z., & Lin, H. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01095.x · Cited by 37
Sahu, S., & Mohapatra, S. (2012) · Dalton Transactions · doi:10.1039/c2dt31812a · Cited by 37
Cui, J., Li, C., Wang, C., Li, Y., Zhang, L., Zhang, L., Xiu, X., Li, Y., & Wei, N. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22496 · Cited by 36
Hirayama, F., Mieda, S., Miyamoto, Y., Arima, H., & Uekama, K. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js990128i · Cited by 33
Holden, S. N., Beeram, M., Krop, I. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1029 · Cited by 32
New injectable melphalan formulations utilizing (SBE)7m-β-CD or HP-β-CD
Ma, D. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00255-0 · Cited by 28
Núñez, F. A. A., & Yalkowsky, S. H. (1998) · PubMed · Cited by 23
Peng, M., Liu, Y., Zhang, H., Cui, Y., Zhai, G., & Chen, C. (2010) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201090223 · Cited by 20
Zeng, J., Huang, H., Liu, S., Xu, H., Huang, J. T., & Yu, J. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.12.024 · Cited by 18
Cited by
A Review of Curcumin and Its Derivatives as Anticancer Agents
Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051033 · Cited by 949
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 390
Cyclodextrin–Drug Inclusion Complexes: In Vivo and In Vitro Approaches
Carneiro, S., Costa Duarte, F., Heimfarth, L., Siqueira Quintans, J., Quintans-Júnior, L., Veiga Júnior, V., & Neves de Lima, Á. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030642 · Cited by 350
Cyclodextrins: Structural, Chemical, and Physical Properties, and Applications
Poulson, B. G., Alsulami, Q. A., Sharfalddin, A., El Agammy, E. F., Mouffouk, F., Emwas, A.-H., Jaremko, L., & Jaremko, M. (2021) · Polysaccharides · doi:10.3390/polysaccharides3010001 · Cited by 312
Contact Lens Technology: From Fundamentals to Applications
Moreddu, R., Vigolo, D., & Yetisen, A. K. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900368 · Cited by 264
Metadata
- Authors
- Gidwani, B., & Vyas, A.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-15
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2149107062
- Cited by
- 473
- References
- 82
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.